Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

south yarra pharma pty ltd - lincomycin hydrochloride - oral powder, pre-mix - lincomycin hydrochloride antibiotic active 1000.0 g/kg - antibiotic & related

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

south yarra pharma pty ltd - tulathromycin - parenteral liquid/solution/suspension - tulathromycin antibiotic active 100.0 mg/ml - antibiotic & related

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

south yarra pharma pty ltd - chlortetracycline hydrochloride - oral powder, pre-mix - chlortetracycline hydrochloride antibiotic active 950.0 g/kg - antibiotic & related

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

south yarra pharma pty ltd - sodium salicylate - oral powder, pre-mix - sodium salicylate phenol active 1000.0 g/kg - musculoskeletal system

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

south yarra pharma pty ltd - tilmicosin phosphate - parenteral liquid/solution/suspension - tilmicosin phosphate antibiotic active 300.0 mg/ml - antibiotic & related

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

south yarra pharma pty ltd - meloxicam - parenteral liquid/solution/suspension - meloxicam ungrouped active 20.0 mg/ml - musculoskeletal system

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - isotretinoin, quantity: 20 mg - capsule, soft - excipient ingredients: soya oil; yellow beeswax; hydrogenated soya oil; partially hydrogenated soya oil; gelatin; glycerol; titanium dioxide; iron oxide red; iron oxide yellow; propylene glycol; brilliant blue fcf; ethanol; purified water; shellac; strong ammonia solution - treatment of severe cystic acne. a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - isotretinoin, quantity: 10 mg - capsule, soft - excipient ingredients: soya oil; yellow beeswax; hydrogenated soya oil; partially hydrogenated soya oil; gelatin; glycerol; titanium dioxide; iron oxide red; iron oxide yellow; propylene glycol; brilliant blue fcf; ethanol; purified water; shellac; strong ammonia solution - treatment of severe cystic acne. a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - prasugrel, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; crospovidone; microcrystalline cellulose; croscarmellose sodium; sucrose stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red - prasugrel, co-administered with aspirin, is indicated for the prevention of atherothrombotic events (myocardial infarction, stroke and cardiovascular death) in patients with acute coronary syndromes (moderate to high risk unstable angina (ua), non st-segment elevation myocardial infarction (nstemi) or st-segment elevation myocardial infarction (stemi)) who are to undergo percutaneous coronary intervention (pci).

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - prasugrel, quantity: 5 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; crospovidone; microcrystalline cellulose; lactose monohydrate; sucrose stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow - prasugrel, co-administered with aspirin, is indicated for the prevention of atherothrombotic events (myocardial infarction, stroke and cardiovascular death) in patients with acute coronary syndromes (moderate to high risk unstable angina (ua), non st-segment elevation myocardial infarction (nstemi) or st-segment elevation myocardial infarction (stemi)) who are to undergo percutaneous coronary intervention (pci).